Clinical Trial Update: Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating CFZ533 (iscalimab), an anti-CD40 monoclonal antibody, in kidney transplant recipients to assess efficacy, safety, tolerability, PK and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• CFZ533 (iscalimab) (iscalimab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Kidney Transplantation | Phase 2 | Status: COMPLETED | Results posted: 2026-03-23